Prevalence and risk factors associated with metabolic dysfunction-associated steatohepatitis in patients with Helicobacter pylori infection: A population-based study

doi:10.4254/wjh.v16.i10.1169

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 10

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (787)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-1) series, Tables (1-1) series.

Item

Count

PDF

HTML

515

Figures (1-1)

Tables (1-1)

Sum=599

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=144

Publishing Process of This Article

Item

Count

Browse

Download

Sum=22

Oct 27, 2024 (publication date) through Nov 5, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Case Control Study

World J Hepatol. Oct 27, 2024; 16(10): 1169-1176
Published online Oct 27, 2024. doi: 10.4254/wjh.v16.i10.1169

Table 1 Baseline characteristics of patients with metabolic dysfunction-associated steatohepatitis and control, n (%)

	MASH	No MASH
Smoker	8650 (14.03)	3629290 (5.24)
Male	26020 (42.21)	31483000 (45.51)
Hyperlipidemia	43360 (70.35)	11634530 (16.82)
Hypertension	45520 (73.86)	13997560 (20.23)
T2DM	34800 (56.46)	5552250 (8.02)
Obesity	35840 (58.15)	5123940 (7.40)
H. pylori infection	570 (0.92)	79420 (0.11)
Total	61630	69170990

H. pylori infection: Helicobacter pylori infection; T2DM: Type 2 diabetes mellitus; MASH: Metabolic dysfunction-associated steatohepatitis.

Citation: Abdel-Razeq R, Bitar L, Bitar ER, Onwuzo C, Abu-Hammour MN, Eren B, Mohamed I, Johnson A, Boustany A, Onwuzo S, Asaad I. Prevalence and risk factors associated with metabolic dysfunction-associated steatohepatitis in patients with Helicobacter pylori infection: A population-based study. World J Hepatol 2024; 16(10): 1169-1176
URL: https://www.wjgnet.com/1948-5182/full/v16/i10/1169.htm
DOI: https://dx.doi.org/10.4254/wjh.v16.i10.1169